Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism

Thomas Delate, Malti Charlu,Shiyun Zhu, Ashok Pai,Nathan P. Clark,Daniel M. Witt,Jackson M. King,Jordan B. King

Thrombosis Research（2020）

引用 0|浏览2

暂无评分

摘要

•Historically, cancer-associated VTE was treated with LMWH or UFH.•From 2000 to 2017, first-line LMWH and DOAC use increased while warfarin decreased.•DOAC and LMWH cost-effectiveness analyses compared to warfarin should be conducted.

查看译文

关键词

Anticoagulant agents,Venous thromboembolism,Cancer,Therapeutics,Time

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要